Successful Desensitization in a Pediatric Patient with Cytarabine Anaphylaxis

Creative Commons License

Aytekin Güvenir F., ŞENGÜL EMEKSİZ Z., Gültekin E. S., Güzelküçük Z., ÖZBEK N. Y., DİBEK MISIRLIOĞLU E.

Asthma Allergy Immunology, cilt.23, sa.1, ss.96-99, 2025 (ESCI, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 1
  • Basım Tarihi: 2025
  • Doi Numarası: 10.21911/aai.2025.658
  • Dergi Adı: Asthma Allergy Immunology
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.96-99
  • Anahtar Kelimeler: Desensitization, anaphylaxis, cytarabine (ARA-C)
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Cytarabine (ARA-C) is a chemotherapeutic agent used in the treatment of hematologic malignancies. Although infusion reactions are generally observed with ARA-C, IgE and non-IgE-mediated hypersensitivity reactions have also been reported. Anaphylaxis was observed on the 3rd dose of ARA-C treatment in a 17-year-old patient diagnosed with acute myeloid leukemia. There was no alternative treatment option for his malignant disease, and we decided to conduct ARA-C desensitization. We would like to describe a successful desensitization protocol in a pediatric patient who experienced anaphylaxis during ARA-C infusion.